Hongwei Xu

Researcher

University of Arkansas for Medical Sciences

faculty

2 h-index 13 pubs 28 cited

Research Areas

Multiple Myeloma Research and Treatments Cancer-related molecular mechanisms research Genomics and Phylogenetic Studies Immune Response and Inflammation Health disparities and outcomes Meta-analysis and systematic reviews Molecular Biology Techniques and Applications Bone health and treatments

Links

ORCID

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Hongwei Xu's research investigates molecular mechanisms underlying cancer development and progression, with a particular focus on multiple myeloma. Recent publications explore the role of extracellular vesicles and specific microRNAs in inhibiting tumor growth and the regulatory mechanisms involved. Xu has also contributed to understanding gene signatures that predict the risk of monoclonal gammopathy of undetermined significance (MGUS) progressing to multiple myeloma. Other work examines the impact of Cystatin M/E on bone resorption in multiple myeloma and analyzes multi-omics data to reveal alterations in the immune microenvironment during disease progression and its precursor stages. The research also addresses survival disparities in Black Americans with multiple myeloma and identifies risk factors for disease progression in this population. Xu's scholarly metrics include an h-index of 2, with 13 total publications and 28 total citations. Key collaborators include David E. Mery, Visanu Wanchai, Fumou Sun, and John D. Shaughnessy Jr., all from the University of Arkansas for Medical Sciences.

Metrics

h-index: 2
Publications: 13
Citations: 28

Selected Publications

Cystatin M/E Ameliorates Multiple Myeloma-Induced Hyper Osteolytic Bone Resorption (2025) DOI
Identification of Risk Factors for Myeloma Progression in African American Patients (2024) DOI
Single Nuclei Multiomic Profiling of Transcriptional and Chromatin Accessibility of Tumor Cells Underlines Extensive Cis-Regulatory Interaction during Multiple Myeloma Progression (2024) DOI
The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans (2024) DOI
Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages (2024) DOI
Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression (2024) DOI
A gene signature can predict risk of MGUS progressing to multiple myeloma (2023) DOI
A Gene Signature Can Predict Risk of MGUS Progressing to Multiple Myeloma (2023) DOI
A 12 Gene Signature Accurately Predicts Multiple Myeloma Progression from Monoclonal Gammopathy of Undetermined Significance (2022) DOI
Extracellular vesicle expansion of <i>PMIS‐miR‐210</i> expression inhibits colorectal tumour growth via apoptosis and an XIST/NME1 regulatory mechanism (2022) DOI